Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 5018 results found since Jan 2013.

Vaccination against SARS-CoV-2 in patients with multiple sclerosis
CONCLUSION: The data available make it possible to recommend mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. In patients on fingolimod, cladribine, alemtuzumab, ocrelizumab and rituximab, vaccination prior to the initiation of medication administration would be recommendable whenever possible.PMID:33764494 | DOI:10.33588/rn.7207.2021097
Source: Revista de Neurologia - March 25, 2021 Category: Neurology Authors: L Costa Frossard-Fran ça J M Garc ía-Domínguez I Moreno-Torres J Fort ún L M Villar V Meca-Lallana Source Type: research

Rituximab for thyroid-associated ophthalmopathy
CONCLUSIONS: There is currently insufficient evidence to support the use of RTX in people with TAO. Future studies investigating RTX in people with active TAO may need to be multi-centre in order to recruit enough participants to make an adequate judgement on the efficacy and safety of this novel therapy.PMID:35709102 | DOI:10.1002/14651858.CD009226.pub3
Source: Cochrane Database of Systematic Reviews - June 16, 2022 Category: General Medicine Authors: Swan Kang Shirin Hamed Azzam Neda Minakaran Daniel G Ezra Source Type: research

Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: a systematic review
CONCLUSION: Overall, our systematic review provides important insights into the potential cardiovascular benefits of biologic and targeted synthetic treatments for RA by a still unknown mechanism. These findings can inform clinical practice and contribute to our understanding of their possible effects on early vascular pathology. Key Points • Great heterogeneity of methods are used to evaluate the endothelial function and arterial stiffness in patients with RA on biologic and targeted synthetic antirheumatic drugs. • Most studies have shown a considerable improvement in endothelial function and arterial stiffness with ...
Source: Atherosclerosis - March 29, 2023 Category: Cardiology Authors: Georgi Gerganov Tsvetoslav Georgiev Maria Dimova Tanya Shivacheva Source Type: research

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
Conclusion Hem-irAEs are potentially life-threatening complications of ICIs that require a high level of clinical suspicion. Ir-TCP is amongst the most frequently reported hem-irAEs. Due to its low incidence and the lack of specific diagnostic criteria, ir-TCP may be underdiagnosed and possibly underreported. The diagnosis is based on exclusion of other causes of TCP together with clinical features that suggest an immune event such as the refractoriness to platelet transfusions and response to corticosteroids. During clinical development, a systematic analysis of ir-TCP cases at clinical study and program level is of outm...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research

Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis
Conclusion: In RA, RF positivity predicts better response to RTX and TCZ but not to ABT.
Source: Seminars in Arthritis and Rheumatism - January 3, 2013 Category: Rheumatology Authors: R.J. Maneiro, Eva Salgado, Loreto Carmona, Juan J. Gomez-Reino Tags: Rheumatoid Arthritis Source Type: research

Interventions for renal vasculitis in adults.
CONCLUSIONS: Plasma exchange was effective in patients with severe AKI secondary to vasculitis. Pulse cyclophosphamide results in an increased risk of relapse when compared to continuous oral use but a reduced total dose. Whilst cyclophosphamide is standard induction treatment, rituximab and mycophenolate mofetil were also effective. Azathioprine, methotrexate and leflunomide were effective as maintenance therapy. Further studies are required to more clearly delineate the appropriate place of newer agents within an evidence-based therapeutic strategy. PMID: 26400765 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 24, 2015 Category: Journals (General) Authors: Walters G, Willis NS, Craig JC Tags: Cochrane Database Syst Rev Source Type: research

Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.
CONCLUSIONS: To treat HCV-associated mixed cryoglobulinaemia, it may be beneficial to eliminate HCV infection by using antiviral treatment and to stop the immune response by using rituximab. For skin vasculitis and for some laboratory findings, it may be appropriate to combine antiviral treatment with deletion of B-cell clonal expansions by using of rituximab. The applicability of evidence reviewed here is limited by the absence of any studies with direct-acting antivirals, which are urgently needed to guide therapy. PMID: 29734473 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 7, 2018 Category: General Medicine Authors: Montero N, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, Soler MJ Tags: Cochrane Database Syst Rev Source Type: research

Quadruple Hit Lymphoma: A Rare Entity with Dismal Prognosis
ConclusionQuadruple hit lymphoma is an extremely rare entity occurring in patients diagnosed with high-grade B cell lymphoma with the rearrangements of four genes: MYC, BCL2, BCL6 and CCND1. Most patients present with bone marrow involvement, high IPI score and extra-nodal disease. There is no consensus on the optimal treatment and the prognosis is dismal despite aggressive initial therapy.Table.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Proulx, J., Denley, R., Pedemonte, B. M., Shah, A. A., Ochs, R., Haigentz, M., Alistar, A. T., Early, E., Whitman, E. D., Cherry, M. Tags: 621. Lymphoma-Genetic/Epigenetic Biology Source Type: research